Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients. - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Leukemia Research Année : 2011

Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients.

Résumé

This report aims to more accurately define the frequency of the involvement of SRC Family Kinases (SFKs) in imatinib- and dasatinib-resistant CML patients. Clinical samples were analysed during in vivo treatment. We confirmed the high frequency of SFKs involvement in Tyrosine kinase inhibitor-resistant CML (52% of the cases) and even further in progressive disease and blast crises (60% of the cases). The SFKs deregulation is also observed in patients harboring BCR-ABL mutations. In T315I and F317L mutated patients, CML-resistance appears to be promoted by SFKs kinase protein reactivation once the BCR-ABL mutated clone has decreased on Omacetaxine.

Domaines

Cancer

Dates et versions

hal-00831439 , version 1 (07-06-2013)

Identifiants

Citer

Sandrine Hayette, Kaddour Chabane, Mauricette Michallet, Estelle Michallat, Pascale Cony-Makhoul, et al.. Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients.. Leukemia Research, 2011, 35 (1), pp.38-43. ⟨10.1016/j.leukres.2010.06.030⟩. ⟨hal-00831439⟩
75 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More